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Received 30 July 2007; received in revised form 28 September 2007; accepted 8 October 2007Abstract The molecular mechanisms controlling DNA-damage-induced apoptosis of human embryonic stem cells (hESC) are
poorly understood. Here we investigate the role of p53 in etoposide-induced apoptosis. We show that p53 is constitutively
expressed at high levels in the cytoplasm of hESC. Etoposide treatment results in a rapid and extensive induction of apoptosis
and leads to a further increase in p53 and PUMA expression as well as Bax processing. p53 both translocates to the nucleus and
associates with the mitochondria, accompanied by colocalization of Bax with Mcl1. hESC stably transduced with p53 shRNA
display 80% reduction of endogenous p53 and exhibit an 80% reduction in etoposide-induced apoptosis accompanied by
constitutive downregulation of Bax and an attenuated upregulation of PUMA. Our data further show that undifferentiated hESC
that express Oct4 are much more sensitive to etoposide-induced apoptosis than their more differentiated progeny. Our study
demonstrates that p53 is required for etoposide-induced apoptosis of hESC and reveals, at least in part, the molecular
mechanism of DNA-damage-induced apoptosis in hESC.
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Human embryonic stem cell (hESC) lines are established from
the inner cell mass of the blastocyst and differentiate into all
cell lineages of the body. Although hESC grown under stan-
dard culture conditions on full-density feeder layers display
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doi:10.1016/j.scr.2007.10.003genetic stability and do not show morphological changes
characteristic of transformation. This could be due to both
efficient DNA repair and the selective induction of apoptosis
in hESC that have sustained DNA damage. DNA damage res-
ponse and cell-cycle regulation differ markedly between
mouse embryonic stem cells (mESC) and somatic cells (Hong
and Stambrook, 2004). The spontaneous mutation frequency
in mouse somatic cells is approximately 100-fold higher than
in mESC. mESC also lack a G1 checkpoint and are hypersen-
sitive to ionizing radiation and other DNA-damaging agents
(Hong and Stambrook, 2004). These characteristics facilitate
apoptosis and the removal of cells with a mutational burden
from the population..
117Etoposide-induced apoptosis of hESC requires p53The tumor suppressor p53 plays a central role in suppres-
sing tumorigenesis by inducing cell cycle arrest or apoptosis
(Godefroy et al., 2004). Indeed, mutations of the p53 gene
occur in approximately 50% of human cancers (Hollstein
et al., 1991; Hussain and Harris, 1998; Levine, 1997). The
role of p53 in guarding both mouse and human ES cells from
the consequences of DNA-damage apoptosis remains largely
unclear. While some investigators argue that p53 is nonfunc-
tional in undifferentiated mESC (Aladjem et al., 1998),
others show that p53 is involved in both UV-induced apoptosis
(Chao et al., 2000; Xu et al., 2002) and differentiation
(Sabapathy et al., 1997). Recently p53 was shown to be
involved in UV-induced apoptosis of hESC (Qin et al., 2007)
without modulation of p53 target gene expression.
The topoisomerase II inhibitor etoposide is an antineo-
plastic drug that has been widely used to couple DNA damage
to apoptosis (Karpinich et al., 2002). Topoisomerase II is a
nuclear enzyme that functions during both DNA replication
and transcription (Hande, 1998). Topoisomerase II prevents
“knots” from forming in DNA by allowing the passage of an
intact segment of the helical DNA through a transient double-
strand break (Burden and Osheroff, 1998). Etoposide sta-
bilizes the complex formed by topoisomerase II and the
5′-cleaved ends of the DNA, thus forming stable (nonre-
pairable) protein-linked DNA double-strand breaks (Bur-
den and Osheroff, 1998). Cells are able to recognize such
DNA damage and, in turn, to eliminate the injured cells
by p53-mediated apoptosis.
Induction of apoptosis by p53 can occur via both transcrip-
tion-independent and transcription dependent pathways.
The classical transcription-dependent pathway involves
stabilization of p53 protein via a range of posttranslational
modifications, nuclear translocation, and subsequent trans-
activation of proapoptotic genes, such as PUMA, Noxa, Bax,
p53, AIP1, Apaf-1, and PERP, as well as repression of anti-
apoptotic genes such as Bcl2 and IAPs (Levine, 1997; Lu,
2005). p53 can also trigger apoptosis via a transcription-
independent pathway that involves rapid translocation of a
proportion of total cellular p53 directly to the mitochondria
and interaction with the Bcl2 family of regulators of mito-
chondrial permeability (Chipuk et al., 2004; Erster et al.,
2004; Leu et al., 2004; Mihara et al., 2003). Here we show
that p53 is required for etoposide-induced apoptosis of hESC
and that the p53 response in these cells involves both mito-
chondrial and nuclear apoptotic pathways.
Results
hESC are very sensitive to etoposide and exhibit
classic apoptotic features
In response to inhibition of topoisomerase II with etoposide,
hESC show an increase in apoptosis in a concentration- and
time-dependent manner (Figs. 1A and 1B). Indeed, hESC ap-
pear to be far more sensitive to etoposide-induced apoptosis
than other cell lines or primary cell cultures (Karpinich et al.,
2002, 2006; Liu and Joel, 2003). As shown in Fig. S2C the
human cell lines HT1080, 293FT, and CFPac-1 treated with
0.17 μM etoposide for 24 h display 3, 12, and 10% TUNEL-
positive apoptotic cells, while hESC (HES-2) displaymore than
70% apoptosis after identical treatment, as also shown in Fig.1B. Etoposide-induced apoptosis of hESC proceeds rapidly,
with more than 70% of hESC undergoing apoptosis after 24 h
incubation in the presence of 170 nM etoposide.
To confirm that hESC display hallmarks of apoptosis in
response to DNA damage (see for review Lawen, 2003), we
incubated hESC cultures with etoposide for various lengths of
time and assessed mitochondrial cytochrome c release into
the cytosol, caspase-3 activation, DNA laddering, and nuclear
condensation. Incubation with etoposide (340 nM) for 3 h
causes an increase in soluble cytochrome c in the cytosol of
hESC, without affecting the total amount of intracellular
cytochrome c (Fig. 1C). Furthermore, using an antibody
specific to activated caspase-3we show that hESC treatedwith
etoposide for 3 h display caspase-3 activation and that this
activation is inhibited by the general caspase inhibitor zVAD-
fmk (Fig. 1D). By 3 to 4 h after addition of etoposide, hESC start
to display the classical 210-bp DNA laddering pattern of
apoptosis accompanied by the nuclear condensation (Fig. 1E)
and fragmentation typical of apoptosis (Fig. 1F). There is no
increase in necrotic cells over the time period during which we
observed the four diagnostic features of apoptosis (Fig. 1G).Etoposide-induced apoptosis of hESC requires
caspase activation and is partially sensitive to
cycloheximide
Cultures of hESC display a high rate of “spontaneous” apo-
ptosis, with 15% of hESC undergoing apoptosis daily under
optimal culture conditions. Caspases are centrally involved
in the regulation and execution of the apoptotic program
(Thornberry and Lazebnik, 1998) and caspase-3 is activated
in etoposide-treated hESC cultures (Fig. 1D). To determine
whether caspases play a functional role in etoposide-induced
and spontaneous apoptosis of hESC, we incubated hESC with
the general caspase inhibitor zVAD-fmk prior to etoposide
treatment. As shown in Fig. 1H, zVAD-fmk totally inhibits
etoposide-induced, but not spontaneous, apoptosis of hESC.
Similarly, cycloheximide, an inhibitor of protein translation,
is able to prevent 50% of etoposide-induced apoptosis but has
no effect on spontaneous apoptosis. These data therefore
indicate that hESC treated with etoposide undergo caspase-
and protein translation-dependent apoptosis, whereas spon-
taneous apoptosis proceeds via caspase- and translation-
independent pathways.
We did not observe any effect of bongkrekic acid (data not
shown), an inhibitor of the adenine nucleotide translocator
and mitochondrial permeability transition pore formation
(Pastorino and Hoek, 2000; Scarlett et al., 2000), on spon-
taneous or etoposide-induced apoptosis of hESC. In agree-
ment with this observation, we could not detect any loss of
mitochondrial membrane potential, measured by JC-1 up-
take, during the first 4 h of induction of apoptosis with
etoposide (data not shown), despite the fact that cyto-
chrome c release in the cytosol was already detected at 3 h.
Cyclosporin A, an inhibitor of both mitochondrial perme-
ability transition and calcineurin, induced apoptosis by itself
and did not inhibit etoposide-induced apoptosis (results not
shown). Preincubation with leptomycin B, a nuclear export
inhibitor, or cyclic pifithrin-α, a purported inhibitor of p53-
mediated transcription (Komarov et al., 1999), also had no or
only a very minor inhibitory effect on etoposide-induced
118 C. Grandela et al.hESC apoptosis. This is perhaps not surprising since the effi-
cacy of pifithrin-α as an inhibitor of p53 transactivation
activity is highly questionable (Walton et al., 2005). Pifithrin-μ, a compound that inhibits association of p53 with mito-
chondria (Strom et al., 2006), was found to reduce etoposide
induced apoptosis of hESC by 50% (Fig. 1H).
Figure 2 Differentiation of hESC reduces their sensitivity to
etoposide-induced apoptosis. HES-4 cells were treated with
170 nM etoposide and harvested after 2, 4, 6, 9, 12, or 18 h. The
etoposide-treated hESC were double-labeled with TUNEL and
the stem cell marker Oct4 and analyzed by flow cytometry (see
Supplemental Fig. S2A). The data are expressed as the per-
centage of surviving (TUNEL-negative) cells in the Oct4-positive
and Oct4-negative fraction of the hESC culture. The results
represent the means±SD (n=3). Similar results were obtained
for HES-2 cells.
119Etoposide-induced apoptosis of hESC requires p53The state of differentiation of hESC affects their
sensitivity to etoposide-induced apoptosis
hESC cultured on mouse embryonic fibroblast feeder cells
in the presence of knockout serum replacement+4 ng/ml
b-FGF (Amit et al., 2004) appear to be a morphologically
homogeneous population of undifferentiated cells. However,
hESC cultured under these conditions are heterogeneous and
display various degrees of differentiation as judged by the
expression of the stem cell marker Oct4 when assayed by
immunofluorescence and flow cytometry (Figs. S1 and S2).
Cells at the outer rim of the hESC colonies display reduced
expression of Oct4 and are more resistant to etoposide-
induced apoptosis than undifferentiated hESC in the center
of the colonies (Fig. S1A).
To quantify this phenomenon, we double-labeled etopo-
side-treated HES-2 and HES-4 cells with both TUNEL and
antibody directed against the stem cell marker Oct4. As
shown in Fig. 2, the survival of the Oct4-expressing hESC
(∼70% of the culture) was reduced to less than 10% within
18 h after etoposide treatment, which was accompanied by
an increase in apoptosis from 10 to 70%. Within this time
frame the proportion of surviving Oct4-negative cells was
not significantly reduced, indicating that differentiated
hESC are much more resistant to etoposide-induced apo-
ptosis than their less differentiated counterparts. To high-
light this effect of differentiation status on apoptosis we
show the results for the HES-4 cell line, which displays a
higher degree of spontaneous differentiation than other
hESC lines. Similar results were obtained for the HES-2 cell
line (data not shown).
Expression analysis of several pro- and
antiapoptotic proteins in hESC
To determine whether hESC express established regulators
of p53-dependent apoptosis, we used immunostaining of in
situ-fixed hESC cultures to detect proteins that are knownFigure 1 hESC are very sensitive to etoposide and exhibit class
between 0.1 and 17 μM for 18 h or (B) 170 nM etoposide for various t
and HES-2 (B) cells were harvested after treatment, TUNEL stained,
percentage means±SD (n=3). (C) Cytochrome c release. HES-2 ce
permeabilized with digitonin. Proteins in the soluble (S—supernatan
15% polyacrylamide gels and Western blotting was performed with
GAPDH (cytosolic protein) antibodies. (D) Caspase-3 activation. HES
30 min and then treated with 340 nM etoposide for 3 h. PFA-fixed ad
nuclei visualized with DAPI. Scale bars, 200 μm. (E) DNA laddering. H
apoptotic bodies and cells were harvested at the indicated time point
DNA ladder (Invitrogen) was used as a size standard. (F) Chromatin c
6 h, fixed with 4% PFA, and stained with DAPI. The arrow indica
fragmented appearance of an apoptotic cell. Scale bar, 50 μm. (G) E
340 nM etoposide for up to 6 h and apoptotic bodies and cells harves
green fluorescence reactive dye (LIVE/DEAD Fixable Dead Cell stain)
PFA, and analyzed by flow cytometry. A representative experiment o
preincubated with vehicle alone or with inhibitor (25 μM zVAD-fmk for
α (cPFT) for 1 h, or 10 μM pifithrin-μ for 1 h) and subsequently expose
harvested, stained with TUNEL, and analyzed by flow cytometry. Resu
were obtained with HES-4 cells in each assay.to possess apoptotic or antiapoptotic activities. Fig. 3
shows that p53, Hdm2, Hdm4, Mcl1, Bax, and p14ARF are
expressed in the HES-4 cell line, whereas Bcl2 was
undetectable. Similar results were obtained for the HES-2
and HES-3 cell lines. In the majority of undifferentiated
hESC, p53 has a cytoplasmic localization with only very few
cells at the edge of the colonies displaying nuclear p53
staining detected by the DO-1 antibody. Similar results
were obtained using a different anti-p53 antibody
(pAB1801; Figs. 3B and 3C). The high levels of cytoplasmic
expression of p53 in untreated hESC were confirmed by
Western blotting of cytosolic protein extracts from hESC
(Fig. 1C).ic apoptotic features. (A) Increasing etoposide concentrations
ime points between 3 and 24 h. Floating and adherent HES-3 (A)
and analyzed by flow cytometry. Results shown are expressed as
lls were treated with 340 nM etoposide for 1, 2, or 3 h and
t) and insoluble (P—pellet) fractions were resolved on separate
p53, cytochrome c, lamin B (nuclear membrane protein), and
-2 cells were preincubated with 25 μM zVAD-fmk or vehicle for
herent colonies were immunostained for cleaved caspase-3 and
ES-2 cells were treated with 340 nM etoposide for 2 to 18 h and
s. DNAwas collected and separated on a 1.5% agarose gel. A 1 kb
ondensation. HES-2 cells were treated with 340 nM etoposide for
tes a human embryonic stem cell with the typical condensed
toposide does not induce necrosis. HES-2 cells were treated with
ted at the indicated time points. Cells were then incubated with
diluted in KSR medium for 30 min on ice in the dark, fixed in 3.7%
f three independent experiments is shown. (H) HES-2 cells were
30 min, 1 μg/ml cycloheximide for 30 min, 10 μM cyclic pifithrin-
d to 170 nM etoposide for 18 h. Floating and adherent cells were
lts are expressed as percentage means±SD (n=3). Similar results
Figure 3 hESC exhibit a cytosolic localization of p53 and express Mcl1, Bax, p14ARF, Hdm4, and Hdm2 under standard culture
conditions. (A) HES-4 colonies were fixed and immunostained for p53, Mcl1, Bax, p14ARF, Hdm4, and Hdm2. (B) and (C) represent
higher magnifications of colonies immunostained with the antibodies p53 DO-1 and p53 pAB1801, respectively. Representative
examples of three independent experiments are shown. Similar results were obtained with HES-2 and HES-3 cells. Scale bars, 200 μm.
120 C. Grandela et al.Etoposide-induced apoptosis in hESC dramatically
alters subcellular localization of p53, Bax, and Mcl1
In untreated undifferentiated hESC, p53 resides mainly in the
cytosol in two forms, a soluble fraction and a particulate
fraction, as judged by immunofluorescence detection
(Fig. 3A) and cell fractionation (Fig. 1C). Four hours after
etoposide treatment we detect colocalization of p53 with the
mitochondrial marker antibody 1E6 (Banbury, 1994), suggest-
ing that p53 associates with this organelle. During incubation
with etoposide, the subcellular localization of the mitochon-
dria themselves changes from a small punctate distribution
throughout the cytosol to large aggregates of mitochondria in
a perinuclear region that stain strongly for p53. Simulta-
neously, an increasing proportion of hESC display nuclear
staining for p53 (Figs. 4A and 4B). These observations suggestFigure 4 hESC show redistribution of cytosolic p53 to mitochondria
apoptosis with etoposide. (A) HES-2 cells were exposed to 340 nM et
nuclei (DAPI). Representative examples of three independent experi
Scale bars, 100 μm. (B) Confocal microscope images of HES-2 cells
cytosol to the nucleus as well as to the mitochondria (1E6 is a mitoch
to 340 nM etoposide for 3 and 18 h, PFA-fixed, and immunostained fo
etoposide, Mcl1 and Bax colocalize in a perinuclear region in structu
(control and 3 h 340 nM etoposide) and 50 μm (18 h 340 nM etoposidthat p53 translocates both to the mitochondria and to the
nucleus in response to etoposide treatment. One of the
prerequisites of mitochondrial permeability transition and
cytochrome c release is thought to be the insertion of Bax into
the outer mitochondrial membrane. When we examined the
subcellular localization of Bax and Mcl1 between 3 and 18 h
after etoposide treatment, Bax increasingly colocalized with
Mcl1 in perinuclear structures reminiscent of the mitochon-
drial aggregates described above (Fig. 4C).
Altered expression of key apoptosis regulators upon
etoposide-induced apoptosis in hESC
In most model systems, etoposide-induced apoptosis is de-
pendent on p53 (Karpinich et al., 2002; Lowe et al., 1993; Yin
et al., 2000). In agreement with these previous observations,and nucleus and colocalization of Mcl1 and Bax upon induction of
oposide for 3 or 18 h, PFA-fixed, and immunostained for p53 and
ments are shown. Similar results were obtained with HES-4 cells.
treated with 340 nM etoposide for 4 h. p53 relocalizes from the
ondrial marker). Scale bars, 50 μm. (C) HES-4 cells were exposed
r Mcl1, Bax, and nuclei (DAPI). Upon induction of apoptosis with
res reminiscent of mitochondrial aggregates. Scale bars, 100 μm
e).
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122 C. Grandela et al.we detect an increase in p53 expression as early as 3 h after
etoposide addition. Expression of p53 then peaks around 6–
9 h of exposure to etoposide and wanes thereafter (Fig. 5A).
PUMA, one of the downstream targets of p53, is upregulated
between 4.5 and 6 h after exposure to etoposide, as is nuclear
p53. Furthermore, consistent with the release of cytochrome
c at 3 h after exposure to etoposide, increased activation of
caspase-3 is maintained for 6 to 8 h after etoposide addition.
Similar kinetics of upregulation was observed for Hdm2. By
contrast, no alteration in Mcl1, Hdm4, Noxa, or Oct4 expres-
sion was found in etoposide-treated hESC (Fig. 5A). However,
Nanog was downregulated in hESC after etoposide-induced
upregulation of p53, in agreement with the previously re-
ported (Lin et al., 2005) ability of p53 to suppress Nanog
expression in mESC. We detect no, or only very slight, upre-
gulation of the p53 target Bax in response to etoposide
treatment but a clear increase in processing of Bax to the
more potent proapoptotic 18-kDa form with time (Gao and
Dou, 2000; Wood and Newcomb, 2000). We did not detect
expression of p21, a potential downstream target of p53
involved in cell cycle arrest in many cellular model systems,
in either untreated or etoposide-treated hESC by Western
blotting or immunofluorescence (data not shown). This was
not due to an inability of the antibody to detect p21, since we
could detect robust expression of p21 in protein extracts of
human embryonic fibroblasts (data not shown). Since cyclo-
heximide is able to inhibit 50% of etoposide-induced apo-
ptosis, we were interested in determining how this relates to
the expression of p53-regulated apoptosis modulators. As
shown in Fig. 5B preincubation with cycloheximide does not
prevent the upregulation of p53, suggesting that themajority
of its increased expression is due to increased stabilization of
p53 protein and not to de novo synthesis. However, the
expression of Bax, PUMA, and Mcl1 is clearly reduced by this
protein synthesis inhibitor, suggesting that Bax and PUMAmay
be important determinants of etoposide-induced apoptosis of
hESC.
p53 is required for etoposide-induced apoptosis
To investigate the role of p53 in etoposide-induced apoptosis
of hESC we stably transduced HES-2 hESC with a lentivirus
carrying short hairpin RNA (shRNA) designed to knock down
p53 mRNA. As shown in Figs. 6B and 6C, p53 shRNA-
transduced hESC (i) constitutively express only 20% of p53
protein compared to untransduced or control GFP shRNA-
transduced hESC and (ii) display a reduced upregulation of
p53 in response to etoposide addition. These data are
consistent with the 80% reduction in etoposide-induced
apoptosis observed in p53 shRNA-transduced hESC (Fig.
6A). These data demonstrate that etoposide-induced apop-
tosis of hESC is dependent on p53. The reduction of p53-
dependent apoptosis in the p53 shRNA-transduced hESC is
accompanied by a constitutive downregulation of Bax
expression and an attenuated upregulation of PUMA in
response to etoposide addition. These data therefore
strongly suggest that the reduction of etoposide-induced
apoptosis in p53-knockdown hESC is due to a reduced
upregulation of PUMA and a constitutively reduced expres-
sion of Bax. The reduced sensitivity of the p53 shRNA-
transduced hESC to etoposide-induced apoptosis is not due to
an increased differentiation.p53 is required for spontaneous apoptosis
Between 10 and 15% of hESC (HES-2, HES-3, and HES-4) grown
under standard serum-free culture conditions (Amit et al.,
2004) undergo spontaneous apoptosis over an 18-h period. As
shown in Fig. 6, HES-2 stably transduced with p53 shRNA and
displaying only 20% residual p53 expression compared to
untransduced or GFP shRNA-transduced hESC display a
reduction in spontaneous apoptosis from 11.4±5.4 to only
2.4±1.0% (Fig. 6A). GFP shRNA-transduced HES-2 cells or
nontransduced hESC continued to display 15% spontaneous
apoptosis, indicating that the reduction in spontaneous
apoptosis is not due to the lentiviral transduction per se.
Although the reason for the relatively high rate of sponta-
neous apoptosis in hESC serum-free culture is unknown, our
data indicate that spontaneous apoptosis is dependent on
p53.
Transcriptome analysis of GFP and p53
shRNA-transduced hESC
Three replicates of hESC (HES-2 and HES-4) transduced with
either GFP or p53 shRNA were FACS sorted using the cell
surface markers CD9 and GCTM2 to obtain a population of
undifferentiated hESC. RNAwas isolated from these fractions
and subjected to microarray analysis on the 46K Human
Illumina platform. The data shown in Fig. S3 demonstrate
that biological replicates of transduced lines display highly
similar transcriptome profiles and that a similar set of genes
was consistently altered between p53 and GFP shRNA-
transduced lines, independent of the HES lines used. Indeed,
70% of differentially expressed genes were found to contain
p53 binding sites in their promoters. A selection of five
consistently differentially expressed genes between GFP and
p53 shRNA-transduced hESC is shown in the table in Fig. S3.
These p53-regulated genes were previously shown to exhibit
binding of p53 to consensus p53 binding sites in their pro-
moters by CHIP analysis (Wei et al., 2006).
Discussion
hESC are highly susceptible to spontaneous and
etoposide-induced apoptosis
p53 is considered a critical regulator of genomic integrity
because of its ability to trigger apoptosis and/or cell cycle
arrest in response to genotoxic stress. Because embryonic
stem cells display remarkable genomic stability and are
highly sensitive to ionizing radiation and other DNA-dam-
aging agents we examined in detail the role of p53 in the
regulation of apoptosis of human embryonic stem cells. To
this end we opted to use etoposide treatment since this drug
has been shown to activate the p53 pathway specifically in
many model systems. Our data demonstrate that etoposide
apoptosis of hESC requires p53. We further show that hESC
display the characteristic features of apoptosis and, like
mESC, are extremely sensitive to both spontaneous and eto-
poside-induced apoptosis. Spontaneous apoptosis of cultured
hESC is mediated by p53, since reduction of p53 expression in
HES-2 causes a commensurate reduction in apoptosis. These
data are in agreement with a recent study by Qin et al.
Figure 6 p53 is required for etoposide-induced apoptosis of
hESC. (A) HES-2 cells were stably transduced with lentivirus
carrying shRNA designed to knock down p53 or GFP. Both p53
shRNA-transduced and GFP shRNA-transduced (control) hESC
were harvested 4.5, 9, and 18 h after treatment with 170 nM
etoposide. Cells were subsequently PFA-fixed, labeled with
TUNEL, immunostained with the stem cell marker Oct4, and
analyzed by flow cytometry. Results shown are expressed as
percentage means±SD (n=4). (B) Downregulation of p53 and p53
downstream targets Bax and PUMA in p53 shRNA-transduced
HES-2 cells. HES-2 cells stably expressing p53 shRNA or GFP
shRNA were harvested 4.5 and 9 h after treatment with 170 nM
etoposide. Protein extracts were boiled in Laemmli buffer,
resolved on separate polyacrylamide gels, and analyzed by
Western blotting with p53, PUMA, Bax, Nanog, and Oct4 anti-
bodies. β-Tubulin was used to ensure equal protein loading.
(C) Quantification of protein expression using software-based
densitometric analysis on cross-reactive bands and the β-tubulin
loading controls. A representative example of three indepen-
dent experiments is shown.
Figure 5 Increased expression of p53, processing of Bax, and
altered expression of p53 downstream targets PUMA, Hdm2, and
Nanog in hESC treated with etoposide. (A) HES-2 cells were
harvested 1.5, 3, 4.5, 6, 9, and 12 h after treatment with 170 nM
etoposide. Protein extracts were resolved on separate poly-
acrylamide gels and Western blotted with antibodies against
p53, PUMA, Bax, cleaved caspase-3, Hdm2, Hdm4, Mcl1, and
Oct4. β-Tubulin was used to ensure equal loading. A representa-
tive example of three independent experiments is shown.
(B) Cycloheximide treatment interferes with etoposide-induced
upregulation of PUMA and Bax in hESC. HES-2 cells were prein-
cubated with (Cyclo) or without 1 μg/ml cycloheximide (Ctl) for
30 min and treated with 170 nM etoposide (Et) for 18 h. Protein
extracts were resolved on separate polyacrylamide gels and
Western blotted with antibodies against p53, Mcl1, Bax, PUMA,
and β-tubulin. A representative example of three independent
experiments is shown.
123Etoposide-induced apoptosis of hESC requires p53(2007), who also showed that spontaneous and UV-induced
apoptosis of hESC is controlled by p53. If p53-mediated
spontaneous apoptosis is involved in eliminating genetically
damaged cells from the stem cell population, reduction of
p53 function should result in an increased frequency of
chromosomal abnormalities and genetic mutations. We are
currently testing this hypothesis. The karyotypes of the GFP
shRNA-transduced control HES-2 and p53 shRNA-transduced
HES-2 cells were found to be normal at weekly passage 13
(results not shown).
124 C. Grandela et al.Differentiation of hESC reduces their sensitivity to
etoposide-induced apoptosis
The sensitivity of hESC (HES-2 and HES-4) to etoposide-in-
duced apoptosis is dependent on their differentiation status.
We show that undifferentiated hESC that express Oct4 are
the least resistant to etoposide-induced apoptosis compared
to their more differentiated progeny. Clearly the reduction
in Oct4 immunoreactivity in apoptotic hESC observed in flow-
cytometric analysis 6–9 h after etoposide treatment is not
due to an increase in differentiation, which proceeds much
more slowly over a period of days. Indeed, when analyzed by
Western blotting, Oct4 protein expression was not reduced
(Fig. S2B). Given the profound effect of the differentiation
status of hESC on their rate of apoptosis we strongly argue
that meaningful data on apoptosis in hESC can be obtained
only when TUNEL-labeled cells are double labeled with at
least one pluripotency marker, as performed in this study. In
agreement with our data, undifferentiated mESC were
recently shown to be more sensitive to O(6)-methylgua-
nine-induced apoptosis than their differentiated counter-
parts (Roos et al., 2007).
Our data further show that p53 has a small but repro-
ducible effect on spontaneous differentiation of cultured
hESC as determined by the slight increase in Oct4 expression
by FACS in p53 shRNA-transduced hESC lines (91.7±3.4%
(n=5)) compared to the GFP shRNA-transduced controls
(83.4±3.2% (n=5), pb0.01), similar to what was observed by
Qin et al. (2007).The mechanism of p53-dependent apoptosis in hESC
Initiation of etoposide-induced apoptosis in hESC commences
around 3 h after etoposide addition with translocation of the
highly expressed cytosolic p53 protein to the mitochondria
and release of cytochrome c. There is no detectable loss of
mitochondrial membrane potential, as judged by the
maintenance of JC-1 red/green fluorescence. Cytochrome
c release from mitochondria without loss of mitochondrial
membrane potential has previously been reported (Finucane
et al., 1999; Grubb et al., 2001; Krohn et al., 1999). Because
caspase-3 is activated at 3 h after etoposide treatment, we
conclude that apoptosome formation and initiation of the
apoptotic cascade has already commenced at this stage. The
dramatic increase in nuclear p53, which occurs at the same
time, suggests that there are two fractions of cytosolic p53
with different functions in apoptosis induction in response to
etoposide: one that associates with the mitochondria and
one that translocates to the nucleus. In support of this idea,
inhibition of p53 association with mitochondria with pifi-
thrin-μ prevents only 50% of etoposide-induced apoptosis of
hESC (Fig. 1H). Nuclear accumulation of p53 is accompanied
by an early upregulation of the p53 target gene PUMA, but
does not cause an increase in p21. This finding may explain
why cells that have initiated apoptosis fail to arrest the cell
cycle in G0/G1 (as indicated by flow-cytometric analysis of
DAPI-stained hESC cultures (data not shown)). In this respect
hESC resemble mouse ES cells (Xu et al., 2002), which also do
not exhibit cell cycle arrest or slowdown upon UV-induced
DNA damage. The fact that we observe modulation of only a
subset of p53 target genes (PUMA, Hdm2, Nanog) in responseto p53 upregulation suggests that p53 exhibits target spe-
cificity, which may be due, for example, to differences in p53
posttranslational modifications, histone modifications, or
interactions with other transcription factors.
Our data are in contrast to the study by Qin et al. (2007),
which indicated that UV- and γ-radiation-induced apoptosis
of hESC, although p53 dependent, does not lead to accu-
mulation of Bax or Hdm2 and does not cause activation of any
p53 downstream target genes in luciferase reporter assays.
The authors postulated that posttranslational modifications
of p53 render the p53 protein transcriptionally inactive
without interfering with p53's ability to repress Oct4 and
Nanog expression. It was consequently concluded that p53
induces apoptosis solely through a mitochondrial pathway.
We find, however, that, similar to what we observe for eto-
poside-induced apoptosis, γ-radiation (1 Gy)-induced apop-
tosis of hESC causes increased p53 expression that is
accompanied by upregulation of the p53 downstream target
genes PUMA and Hdm2 (Fig. S3B). These differences may be
due to intrinsic cell line differences (H1 hESC vs HES-2, HES-
3, and HES-4 in our study), the passage number of the hESC
(p42–68 H1 vs less than p15 in our study), or the method of
propagation (dispase vs collagenase in our study). Indeed,
there is an increasing amount of evidence to suggest that
hESC can adapt to culture conditions with increasing time in
culture (Baker et al., 2007) and that these changes can
impact on the regulation of apoptosis (Herszfeld et al.,
2006). Alternatively, some of the differing data between the
two studies may be due to mechanistic differences between
the responses of hESC to the different apoptotic stimuli,
namely UV irradiation and etoposide treatment (Attardi
et al., 2004). For example, UVB treatment generally causes
activation of p38 and/or wip1 (Takekawa et al., 2000). p38-
mediated phosphorylation and stabilization of p53 can
subsequently cause cytoplasmic sequestration of wild-type
p53, leading to an absence of p53 target gene modulation
(Chouinard et al., 2002), while wip1 expression has been
shown to suppress both p53-mediated transcription and
apoptosis in response to UV radiation (Takekawa et al.,
2000). Neither p38 nor WIP1 has previously been implicated
in etoposide-induced apoptosis.
Microarray analysis of untreated p53 shRNA-knockdown
hESC and GFP shRNA-transduced control hESC shows that
there are highly similar sets of up- and downregulated mRNAs
in both HES-2 and HES-4 p53 shRNA-transduced hESC in three
independent biological replicates (Fig. S3). Bioinformatic
analysis shows that more than 70% of these genes contain p53
binding sites in their promoters. We have highlighted five
p53-regulated genes that were previously shown to bind p53
in their promoters (Wei et al., 2006). These data strongly
suggest that the observed gene expression changes are not
due to viral insertion effects and that even without etoposide
treatment p53 is involved in the regulation of several known
p53-controlled genes.
hESC express high levels of p53 protein in the cytosol under
standard culture conditions. InmESC, cytoplasmic p53protein
translocates inefficiently to the nucleus upon nucleotide
depletion and the cells undergo p53-independent apoptosis in
response to DNA damage. This response is clearly different in
hESC, which show an increase in nuclear p53 expression after
etoposide treatment. Thismay be due to differences between
the DNA-damage response mechanisms in etoposide-treated
125Etoposide-induced apoptosis of hESC requires p53cells and in cells exposed to nucleotide depletion or to intrin-
sic differences betweenmouse and human ES cells. Reduction
of the pool of p53 by lentivirally delivered shRNA leads to a
reduced expression of Bax and an attenuated upregulation of
PUMA after etoposide treatment, suggesting that these pro-
teins may be critical p53 downstream targets for induction of
etoposide-induced apoptosis in hESC. In other model systems
PUMA, a BH3-only derepressor molecule, counteracts the an-
tiapoptotic function of Mcl1 and induces a proapoptotic
conformational change in Bax (Kuwana et al., 2005). BH3-only
Bcl2 family members such as PUMA trigger mitochondrial
cytochrome c release without loss of mitochondrial mem-
brane potential (Shimizu and Tsujimoto, 2000), as is the case
in etoposide-treated hESC. Alternatively PUMA may be in-
volved in the release of mitochondrially associated p53 to
enhance nuclear p53-mediated apoptotic events further, as
recently demonstrated by Chipuk et al. (2005).
hESC represent a unique cellular model to study p53
regulation of apoptosis, given that they are nontransformed
immortal cells with a normal karyotype and cannot be
directly compared to long-established cell lines, in which
apoptosis pathways are intrinsically altered as part of the
transformation process, or even to primary cell cultures,
which display senescence, DNA-damage-induced cell cycle
arrest, and contact inhibition. The regulation and kinetics
of apoptosis in hESC are very similar to those observed for in
vivo-irradiated thymocytes, with a rapid p53 transcription-
independent first wave of apoptosis followed by a second
p53 transcription-dependent wave (Erster et al., 2004) and
a very early upregulation of PUMA and Bax coincident with
caspase-3 activation. Our data suggest that in hESC these
two waves occur either simultaneously or very soon one
after the other. In both model systems, however, the p53-
dependent upregulation of PUMA and Bax appears to be a
critical determinant. We propose a working model for
etoposide-induced apoptosis in hESC (Fig. 7) in which DNA
damage leads to stabilization and increased expression of
p53 followed by translocation of p53 to both the mitochon-Figure 7 A model depicting the role of p53 and p53 downstream ta
response to DNA damage p53 translocates to both the mitochondria,
triggers upregulation of PUMA and maintenance of Bax expression. PU
release without loss of membrane potential and initiation of the apodria, where it possibly interacts with Mcl1, and the nucleus,
where it leads to transcriptional upregulation of PUMA and
maintenance of Bax expression. The 18-kDa processed forms
of Bax and PUMA next cooperate in triggering cytochrome c
release from the mitochondria without loss of membrane
potential and this subsequently leads to activation of a
caspase-3-dependent apoptotic program. The presence of
two simultaneous pathways to induce p53-mediated apop-
tosis may be a failsafe mechanism of hESC to ensure that
abnormal hESC do not contribute to the developing tissues
and the germ line.
Material and methods
Cell culture
hES cell lines HES-2, HES-3, and HES-4 (Reubinoff et al., 2000)
were cultured (a) on a mouse fibroblast feeder (MEF) layer at
a density of 6×104 cells/cm2 in DMEMwith 20% FCS, 1% ITS, 1%
pen/strep, 1% l-glutamine, 1% NEAA, and 0.1 mM β-mercap-
toethanol using mechanical transfer or (b) with a mouse
fibroblast feeder density of 2×104 cells/cm2 in KSR medium
with 20% KO-serum replacement, 1% l-glutamine, 1% NEAA,
4 ng/ml b-FGF, and 0.1 mM β-mercaptoethanol using 4mg/ml
collagenase (Worthington Biochemical) for serial passaging
(Amit et al., 2000). Cells were plated on Matrigel (BD Bio-
sciences) with MEF-conditioned serum replacement medium
as described (Xu et al., 2001). hES cell lines were used only up
to passage 15 when cultured as per Amit et al. (2000) or Xu
et al. (2001).
DNA laddering
hESC and apoptotic bodies were collected and washed with
PBS. DNA laddering was determined using standard protocol 2
as described at http://www.sgul.ac.uk/depts/immunology/
~dash/group/laddering.html.rgets in the regulation of etoposide-induced apoptosis of hESC. In
where it possibly interacts with Mcl1, and the nucleus, where it
MA and Bax subsequently cooperate in facilitating cytochrome c
ptotic cascade. See text for details.
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hESC were washed with PBS and permeabilized with 20 μg/ml
digitonin for 10 min at 37 °C. The cytosolic/soluble fraction
was collected and boiled in Laemmli sample buffer. Cells
were washed twice with PBS and boiled in Laemmli sample
buffer (insoluble fraction).
Immunofluorescence
hESC were fixed with 4% paraformaldehyde (PFA) for 20 min,
washed with PBS, incubated with the primary or isotype-
control antibody at the indicated dilution for least 2 h at
21 °C, and visualized using appropriate secondary fluores-
cent antibodies. Primary antibodies were used at the fol-
lowing dilutions: p53, 1:50 (DO-1; Santa Cruz Biotechnology);
p53, 1:100 (Pab 1801; Abcam); Mcl1, 1:50 (Abcam); Bax, 1:50
(DAKO); cleaved caspase-3 (Asp175), 1:100 (Cell Signaling);
Bcl2, 1:50 (Santa Cruz Biotechnology); Mdm2, 1:50 (Abcam);
p21, 1:50 (BD Pharmingen); Oct4, 1:40 (Santa Cruz Biotech-
nology); and mitochondrial marker antibody 1E6, undiluted
(Banbury, 1994). Cells were subsequently counterstained
with DAPI (1 μg/ml), mounted with Vectashield mounting
medium (Vector), and analyzed using a fluorescence micro-
scope (FluorMicro BX51; Olympus).
Western blotting analysis
hESC were harvested with Cell Dissociation Solution (Sigma)
and boiled in Laemmli buffer. Proteins were separated by
electrophoresis through 12% SDS–PAGE gels and electro-
transferred to Hybond P (Amersham). The membranes were
blocked with 4% skim milk powder and incubated with
primary antibody overnight at 4 °C and reactivity was
visualized using appropriate HRP-conjugated secondary
antibodies and ECL (Amersham). The primary antibodies,
respective dilutions, and sources were p53, 1:1000 (DO-1;
Santa Cruz Biotechnology); Mcl1, 1:1000 (Abcam); Hdm2,
1:1000 (SMP14; Sigma); Hdm4, 1:1000 (Abcam); Bax,
1:1000 (DAKO); cleaved caspase-3 (Asp175), 1:1000 (Cell
Signaling); β-tubulin, 1:50,000 (Sigma); lamin B, 1:1000
(Calbiochem); GAPDH, 1:4000 (Ambion); cytochrome c,
1:200 (BD Pharmingen); PUMA, 1:1000 (Calbiochem); Bcl2,
1:1000 (Santa Cruz Biotechnology); p21, 1:1000 (BD Phar-
mingen). Images were acquired using the Bio-Rad Gel
ChemiDoc XRS System. Last, software-based densitometric
analysis (Gel-Pro Analyser version 3.1; MediaCybernetics)
was performed on cross-reactive bands and the β-tubulin
loading controls.
Apoptosis and flow cytometry analysis
Etoposide (Sigma) was used as an apoptosis-inducing agent.
After the various treatments, adherent cells and floating
cells were harvested with Cell Dissociation Solution (Sigma),
pooled, and pelleted by centrifugation. Suspensions were
subsequently fixed with PFA (2%) and permeabilized with
0.1% Triton X-100 for TUNEL (Roche) labeling as described by
the manufacturer and additional labeling with Oct4 1:40
(Santa Cruz Biotechnology) prior to analysis by flow cyto-
metry (Cytometrics FC 500 System; Beckman Coulter). Cyclicpifithrin-α (c-PFT, 10 μM; Sigma), pifithrin-μ (10 μM; Calbio-
chem), and bongkrekic acid (50 μM; Sigma) were added 1 h
before the treatment with etoposide. zVAD-fmk (25 μM;
Sigma) and cycloheximide (1 μg/ml; Sigma) were added
30 min before the treatment with etoposide.
Measurement of mitochondrial membrane potential
The MitoProbe JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetra-
ethylbenzimidazolylcarbocyanine iodide) assay kit for flow
cytometry (Invitrogen) was used to measure mitochondrial
membrane potential according to the manufacturer's
instructions. Cells were analyzed by flow cytometry (Cyto-
metrics FC 500 System; Beckman Coulter). In control expe-
riments, cells were incubated with the ionophore carbonyl
cyanide 3-chlorophenylhydrazone at 100 μM 5 min prior to
the addition of JC-1.
Cell staining for viability
The LIVE/DEAD Fixable Dead Cell stain kit (green fluores-
cence; Invitrogen) was used to distinguish apoptosis from
necrosis. The assay was performed according to the manu-
facturer's instructions. Cells were analyzed by flow cytome-
try (Cytometrics FC 500 System; Beckman Coulter).
Lentiviral shRNAi
HES-2 cells were transduced with lentivirus carrying shRNA
designed to knock down p53 or GFP using the Block-It Lentiviral
RNAi Expression System (Invitrogen), as described by the
manufacturer. The p53 shRNA sequences used were the fol-
lowing: p53 top strand, 5′-CGCGCACAGAGGAAGAGAAT-
CTCGAAAGATTCTCTTCCTCTGTGTGCGC-3′, and p53 bottom
strand, 5′-AAAAGCGCACAGAGGAAGAGAATCTTTTCGAGAT-
TCTCTCTTCCTCTGTGCGC-3′; GFP top strand, 5′-CACCGAA-
GAAGTCGTGCTGCTTCATCGAAATGAAGCAGCACGACTTCTTC-3′,
and GFP bottom strand, 5′-AAAAGAAGAAGTCGTGCTGCTTCAT-
TTCGATGAAGCAGCACGACTTCTTC-3′.
Cells were plated on Matrigel and infected with lentivirus
(m.o.i. of 3). Selection with blasticidin (5 μg/ml) was per-
formed for 1 week after each infection and cells were trans-
ferred to flasks with MEF feeders at 2×104 cells/cm2 in KSR
medium. Apoptosis assays and Western blotting analysis were
performed as described above.
Acknowledgments
We thank Irene Tellis, Karen Koh, and Linh Nguyen (Monash
University) and Pegah Jamshidi, Lisa Kass, and Tracy Lomas
(ASCC) for expert technical assistance in hESC cell line
culture; Andrew Fryga (ASCC) for discussion on flow cyto-
metry; Ygal Haupt for helpful discussion and suggestions; Joe
Sambrook for critically reading the manuscript; George
Thouas for cyclosporin and CCCP; and João Ramalho-Santos
for facilitating this research. We greatly acknowledge Sean
Grimmond and Gabriel Kolle for their transcriptome and
bioinformatic analyses. This work was supported partially by
the Fundação para a Ciência e a Tecnologia, Portugal, and
Catarina Grandela is a recipient of a Ph.D. fellowship from the
127Etoposide-induced apoptosis of hESC requires p53Fundação para a Ciência e Tecnologia (Portugal). The ASCC is
greatly acknowledged for financial and material support.
Appendix A. Supplementary data
Supplementary data associatedwith this article can be found,
in the online version, at doi:10.1016/j.scr.2007.10.003.
References
Aladjem, M.I., Spike, B.T., Rodewald, L.W., Hope, T.J., Klemm, M.,
Jaenisch, R., Wahl, G.M., 1998. ES cells do not activate p53-
dependent stress responses and undergo p53-independent
apoptosis in response to DNA damage. Curr. Biol. 8, 145–155.
Amit, M., Carpenter, M.K., Inokuma, M.S., Chiu, C.P., Harris, C.P.,
Waknitz, M.A., Itskovitz-Eldor, J., Thomson, J.A., 2000. Clonally
derived human embryonic stem cell lines maintain pluripotency
and proliferative potential for prolonged periods of culture. Dev.
Biol. 227, 271–278.
Amit, M., Shariki, C., Margulets, V., Itskovitz-Eldor, J., 2004. Feeder
layer- and serum-free culture of human embryonic stem cells.
Biol. Reprod. 70, 837–845.
Attardi, L.D., de Vries, A., Jacks, T., 2004. Activation of the p53-
dependent G1 checkpoint response in mouse embryo fibroblasts
dependson the specificDNAdamage inducer.Oncogene23, 973–980.
Baker, D.E., Harrison, N.J., Maltby, E., Smith, K., Moore, H.D., Shaw,
P.J., Heath, P.R., Holden, H., Andrews, P.W., 2007. Adaptation to
culture of human embryonic stem cells and oncogenesis in vivo.
Nat. Biotechnol. 25, 207–215.
Banbury, D.N., 1994. New Monoclonal Antibodies to Visualize Vesi-
cular Compartments. Univ. of Oxford, Oxford. [PhD thesis].
Burden, D.A., Osheroff, N., 1998. Mechanism of action of eukaryotic
topoisomerase II and drugs targeted to the enzyme. Biochim.
Biophys. Acta 1400, 139–154.
Chao, C., Saito, S., Kang, J., Anderson, C.W., Appella, E., Xu, Y., 2000.
p53 transcriptional activity is essential for p53-dependent apo-
ptosis following DNA damage. EMBO J. 19, 4967–4975.
Chipuk, J.E., Bouchier-Hayes, L., Kuwana, T., Newmeyer, D.D., Green,
D.R., 2005. PUMA couples the nuclear and cytoplasmic proapopto-
tic function of p53. Science 309, 1732–1735 (See comment).
Chipuk, J.E., Kuwana, T., Bouchier-Hayes, L., Droin, N.M., New-
meyer, D.D., Schuler, M., Green, D.R., 2004. Direct activation of
Bax by p53 mediates mitochondrial membrane permeabilization
and apoptosis. Science 303, 1010–1014.
Chouinard, N., Valerie, K., Rouabhia, M., Huot, J., 2002. UVB-me-
diated activation of p38 mitogen-activated protein kinase en-
hances resistance of normal human keratinocytes to apoptosis by
stabilizing cytoplasmic p53. Biochem. J. 365, 133–145.
Erster, S., Mihara, M., Kim, R.H., Petrenko, O., Moll, U.M., 2004. In
vivo mitochondrial p53 translocation triggers a rapid first wave of
cell death in response to DNA damage that can precede p53
target gene activation. Mol. Cell. Biol. 24, 6728–6741.
Finucane, D.M., Waterhouse, N.J., Amarante-Mendes, G.P., Cotter,
T.G., Green, D.R., 1999. Collapse of the inner mitochondrial
transmembrane potential is not required for apoptosis of HL60
cells. Exp. Cell Res. 251, 166–174.
Gao, G., Dou, Q., 2000. N-terminal cleavage of bax by calpain gene-
rates a potent proapoptotic 18-kDa fragment that promotes bcl-2-
independent cytochrome C release and apoptotic cell death.
J. Cell. Biochem. 80, 53–72.
Godefroy, N., Lemaire, C., Renaud, F., Rincheval, V., Perez, S., Parvu-
Ferecatu, I., Mignotte, B., Vayssiere, J.L., 2004. p53 can promote
mitochondria- and caspase-independent apoptosis. Cell Death
Differ. 11, 785–787.
Grubb, D.R., Ly, J.D., Vaillant, F., Johnson, K.L., Lawen, A., 2001.
Mitochondrial cytochrome c release is caspase-dependent anddoes not involve mitochondrial permeability transition in didem-
nin B-induced apoptosis. Oncogene 20, 4085–4094.
Hande, K.R., 1998. Etoposide: four decades of development of a
topoisomerase II inhibitor. Eur. J. Cancer 34, 1514–1521.
Herszfeld, D., Wolvetang, E., Langton-Bunker, E., Chung, T.L., Filip-
czyk, A.A., Houssami, S., Jamshidi, P., Koh, K., Laslett, A.L.,
Michalska, A., Nguyen, L., Reubinoff, B.E., Tellis, I., Auerbach,
J.M., Ording, C.J., Looijenga, L.H., Pera, M.F., 2006. CD30 is a
survival factor and a biomarker for transformed human pluri-
potent stem cells. Nat. Biotechnol. 24, 351–357.
Hollstein, M., Sidransky, D., Vogelstein, B., Harris, C.C., 1991. p53
mutations in human cancers. Science 253, 49–53.
Hong, Y., Stambrook, P.J., 2004. Restoration of an absent G1 arrest and
protection from apoptosis in embryonic stem cells after ionizing
radiation. Proc. Natl. Acad. Sci. U. S. A. 101, 14443–14448.
Hussain, S.P., Harris, C.C., 1998. Molecular epidemiology of human
cancer: contribution of mutation spectra studies of tumor
suppressor genes. Cancer Res. 58, 4023–4037.
Karpinich, N.O., Tafani, M., Rothman, R.J., Russo, M.A., Farber, J.L.,
2002. The course of etoposide-induced apoptosis from damage to
DNA and p53 activation to mitochondrial release of cytochrome c.
J. Biol. Chem. 277, 16547–16552.
Karpinich, N.O., Tafani, M., Schneider, T., Russo, M.A., Farber, J.L.,
2006. The course of etoposide-induced apoptosis in Jurkat cells
lacking p53 and Bax. J. Cell. Physiol. 208, 55–63.
Komarov, P.G., Komarova, E.A., Kondratov, R.V., Christov-Tselkov,
K., Coon, J.S., Chernov, M.V., Gudkov, A.V., 1999. A chemical
inhibitor of p53 that protects mice from the side effects of cancer
therapy. Science 285, 1733–1737.
Krohn, A.J., Wahlbrink, T., Prehn, J.H., 1999. Mitochondrial depo-
larization is not required for neuronal apoptosis. J. Neurosci. 1,
7394–7404.
Kuwana, T., Bouchier-Hayes, L., Chipuk, J.E., Bonzon, C., Sullivan,
B.A., Green, D.R., Newmeyer, D.D., 2005. BH3 domains of BH3-
only proteins differentially regulate Bax-mediated mitochondrial
membrane permeabilization both directly and indirectly. Mol.
Cell 17, 525–535.
Lawen, A., 2003. Apoptosis—an introduction. BioEssays 25, 888–896.
Leu, J.I., Dumont, P., Hafey, M., Murphy, M.E., George, D.L., 2004.
Mitochondrial p53 activates Bak and causes disruption of a Bak–
Mcl1 complex. Nat. Cell Biol. 6, 443–450.
Levine, A.J., 1997. p53, the cellular gatekeeper for growth and
division. Cell 88, 323–331.
Lin, T., Chao, C., Saito, S., Mazur, S.J., Murphy, M.E., Appella, E.,
Xu, Y., 2005. p53 induces differentiation of mouse embryonic
stem cells by suppressing Nanog expression. Nat. Cell Biol. 7,
165–171.
Liu, W.M., Joel, S.P., 2003. The schedule-dependent effects of
etoposide in leukaemic cell lines: a function of concentration and
duration. Cancer Chemother. Pharmacol. 51, 291–296.
Lowe, S.W., Ruley, H.E., Jacks, T., Housman, D.E., 1993. p53-
dependent apoptosis modulates the cytotoxicity of anticancer
agents. Cell 74, 957–967.
Lu, X., 2005. p53: a heavily dictated dictator of life and death. Curr.
Opin. Genet. Dev. 15, 27–33.
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pan-
coska, P., Moll, U.M., 2003. p53 has a direct apoptogenic role at
the mitochondria. Mol. Cell 11, 577–590.
Pastorino, J.G., Hoek, J.B., 2000. Ethanol potentiates tumor nec-
rosis factor-alpha cytotoxicity in hepatoma cells and primary rat
hepatocytes by promoting induction of the mitochondrial per-
meability transition. Hepatology 31, 1141–1152.
Qin, H., Yu, T., Qing, T., Liu, Y., Zhao, Y., Cai, J., Li, J., Song, Z., Qu, X.,
Zhou, P., Wu, J., Ding, M., Deng, H., 2007. Regulation of apoptosis
and differentiation by p53 in human embryonic stem cells. J. Biol.
Chem. 282, 5842–5852.
Reubinoff, B.E., Pera, M.F., Fong, C.Y., Trounson, A., Bongso, A.,
2000. Embryonic stem cell lines from human blastocysts: somatic
128 C. Grandela et al.differentiation in vitro [erratum appears in Nat. Biotechnol. 2000
18, 559]. Nat. Biotechnol. 18, 399–404 (See comment).
Roos, W.P., Christmann, M., Fraser, S.T., Kaina, B., 2007. Mouse
embryonic stem cells are hypersensitive to apoptosis triggered by
the DNA damage O(6)-methylguanine due to high E2F1 regulated
mismatch repair. Cell Death Differ. 14, 1422–1432.
Sabapathy, K., Klemm, M., Jaenisch, R., Wagner, E.F., 1997. Regu-
lation of ES cell differentiation by functional and conformational
modulation of p53. EMBO J. 16, 6217–6229.
Scarlett, J.L., Sheard, P.W., Hughes, G., Ledgerwood, E.C., Ku, H.H.,
Murphy, M.P., 2000. Changes in mitochondrial membrane potential
during staurosporine-induced apoptosis in Jurkat cells. FEBS Lett.
475, 267–272.
Shimizu, S., Tsujimoto, Y., 2000. Proapoptotic BH3-only Bcl-2 family
members induce cytochrome c release, but not mitochondrial
membrane potential loss, and do not directly modulate voltage-
dependent anion channel activity. Proc.Natl. Acad. Sci. 97, 577–582.
Strom, E., Sathe, S., Komarov, P.G., Chernova, O.B., Pavlovska, I.,
Shyshynova, I., Bosykh, D.A., Burdelya, L.G., Macklis, R.M.,
Skaliter, R., Komarova, E.A., Gudkov, A.V., 2006. Small-molecule
inhibitor of p53 binding to mitochondria protects mice from
gamma radiation. Nat. Chem. Biol. 2, 474–479.
Takekawa, M., Adachi, M., Nakahata, A., Nakayama, I., Itoh, F.,
Tsukuda, H., Taya, Y., Imai, K., 2000. p53-inducible wip1 phos-phatase mediates a negative feedback regulation of p38 MAPK–
p53 signaling in response to UV radiation. EMBO J. 19, 6517–6526.
Thornberry, N.A., Lazebnik, Y., 1998. Caspases: enemies within. Sci-
ence 281, 1312–1316.
Walton, M.I., Wilson, S.C., Hardcastle, I.R., Mirza, A.R., Workman,
P., 2005. An evaluation of the ability of pifithrin-alpha and -beta
to inhibit p53 function in two wild-type p53 human tumor cell
lines. Mol. Cancer Ther. 4, 1369–1377.
Wei, C.L., Wu, Q., Vega, V.B., Chiu, K.P., Ng, P., Zhang, T., Shahab, A.,
Yong,H.C., Fu, Y.,Weng, Z., Liu, J., Zhao, X.D., Chew, J.L., Lee, Y.L.,
Kuznetsov, V.A., Sung, W.K., Miller, L.D., Lim, B., Liu, E.T., Yu, Q.,
Ng, H.H., Ruan, Y., 2006. A global map of p53 transcription-factor
binding sites in the human genome. Cell 124, 207–219.
Wood, D.E., Newcomb, E.W., 2000. Cleavage of Bax enhances its cell
death function. Exp. Cell Res. 256, 375–382.
Xu, C., Inokuma, M.S., Denham, J., Golds, K., Kundu, P., Gold, J.D.,
Carpenter, M.K., 2001. Feeder-free growth of undifferentiated
human embryonic stem cells. Nat. Biotechnol. 19, 971–974.
Xu, D., Wilson, T.J., Chan, D., De Luca, E., Zhou, J., Hertzog, P.J.,
Kola, I., 2002. Ets1 is required for p53 transcriptional activity in UV-
induced apoptosis in embryonic stem cells. EMBO J. 21, 4081–4093.
Yin, D., Tamaki, N., Kokunai, T., 2000. Wild-type p53-dependent
etoposide-induced apoptosis mediated by caspase-3 activation in
human glioma cells. J. Neurosurg. 93, 289–297.
